article thumbnail

Number of ongoing US drug shortages reaches new high, pharmacist group says

Fierce Pharma

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001. . |

Biopharma 316
article thumbnail

EU pharmaceutical legislation revisions: what are the implications for biopharma?

European Pharmaceutical Review

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted. analysis (Source: L.E.K) About the authors Sean Dyson is a Partner in L.E.K.’s

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

W. Va. judge sides with drug distributors in bellwether opioid trial

MedCity News

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.

Biopharma 101
article thumbnail

Pharma-biotech dealmaking incentives shift amid a continued drought in financing

Clarivate

What do the years 2001, 2007, 2014, and 2022 have in common? Investment strategy Industry commentators in the biopharma industry believe the upcoming years are expected to be a period of increased dealmaking activity. In short, the biotech bubble had burst.

Pharma 52
article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

Chris’s practice for biopharma and pharma clients includes advising on the complex regulatory frameworks and the availability of valuable IP regulatory rights such as orphan‑drug market exclusivity, paediatric rewards, SPCs and regulatory data protection rights. Directive 2001/83 (as amended). EMA Biosimilars Q&A.

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

As a biotech, what work does Innate Pharma do in the biopharma industry? Having joined Innate in 2001, Yannis worked within different roles in R&D, initially as a scientist then team manager, and finally becoming responsible for research programmes. He is a member of the company’s Executive Board.

Pharma 109
article thumbnail

PM360 Announces 2023 Trailblazer Award Winners

PM360

Later in his career he transitioned to the agency side and launched Weisscom Partners in 2001, which ultimately evolved into Real Chemistry. Men’s Health: Nuvan Augustin Dassanaike, Senior Vice President Digital and Marketing Strategy & Operations, Accord BioPharma Nephrology/Urology: W. Braun Medical, Inc.